[The effect of the delta sleep-inducing peptide on NMDA-induced seizure activity in rats].
Shandra. A A AA; Godlevskiĭ. L S LS; Brusentsov. A I AI; Karliuga. V A VA
Key Findings
- DSIP altered the seizure‑inducing potency of NMDA in rats, suggesting an interaction with excitatory amino‑acid receptors.
- The observed changes imply a possible neuroprotective effect of DSIP against excitotoxic damage.
- The study was limited to an animal model with no human dosing or safety data provided.
Practical Outcomes
- For biohackers, the main takeaway is that DSIP may have some brain‑protective properties in theory, but there’s no actionable protocol, dosage, or evidence for humans. Until human studies are available, it remains an interesting hypothesis rather than a usable supplement strategy.
Summary
A study in rats found that giving the delta‑sleep‑inducing peptide (DSIP) changed how the brain reacts to a chemical (NMDA) that normally triggers seizures. The results hint that DSIP might protect brain cells from the harmful over‑activation of certain receptors, but the work was done only in animals and doesn’t give clear guidance for human use.
Abstract
The ED100 of the NMDA inducing clonic seizures (0.53 mcg) or tonic extension of forelimbs (5.02 mcg) increased their efficiency 2.3-fold and 4.46-fold, resp., due to the delta-sleep-inducing peptide administration in rats. The data obtained suggests a neuroprotective effect of the peptide on agonists of excitatory amino acid receptors action.
Study Information
pubmed
1997